--- schema_version: "secwatch.filing_event.v1" accession: "0000950170-23-028324" form_type: "8-K" ticker: null cik: "0001604477" company_name: "SQZ Biotechnologies Co" filed_at: "2023-06-15T23:59:59+00:00" generated_at: "2026-06-14T00:13:48.031561+00:00" event_type: "regulatory" sentiment: "negative" materiality_score: 0.75 calibrated_materiality_score: 0.75 confidence: "high" source: SEC EDGAR --- # SQZ Biotech receives NYSE delisting notice; approves 1-for-10 reverse split ## Summary - NYSE notified SQZ that avg market cap and stockholders' equity each <$50M; company plans to submit cure plan within 45 days. - Shareholders approved reverse stock split at ratio of 1:10 (Board discretion) with 23,057,854 votes for, 476,649 against. - Board set reverse split at 1-for-10, effective July 6, 2023 at 5:00 PM ET; split-adjusted trading begins July 7 under SQZ. - No immediate impact on listing; if plan not accepted, NYSE could initiate delisting proceedings. ## SEC filing metadata - accession: 0000950170-23-028324 - form_type: 8-K - cik: 0001604477 - company_name: SQZ Biotechnologies Co - filed_at: 2023-06-15T23:59:59+00:00 - event_type: regulatory - sentiment: negative - materiality_score: 0.75 - calibrated_materiality_score: 0.75 - confidence: high - sec_items: 3.01, 5.07, 8.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1604477/000095017023028324/0000950170-23-028324-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604477/000095017023028324/sqz-20230612.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0000950170-23-028324 - JSON: https://secwatch.observer/filing/0000950170-23-028324.json - Plain text: https://secwatch.observer/filing/0000950170-23-028324.txt ## Key facts - Listing & Compliance Notices SQZ Biotechnologies Co received a nyse deficiency notice notice regarding other (rules 802.01B). - Exchange: nyse - Notice: deficiency notice - Rules: 802.01B source text: June 12, 2023, SQZ Biotechnologies Company (the “Company”) received written notice (the “NYSE Notification”) from the New York Stock Exchange (the “NYSE”) that the Company is not in compliance with Section 802.01B of the NYSE Listed Company Manual because the average global market capitalization of the Company over a consecutive 30 trading-day period and, at the same time, the Company’s last reported stockholders’ equity were each less than $50 million. The Company plans to notify the NYSE that it intends to submit a plan to cure the deficiency and to return to compliance with the NYSE continu evidence_url: https://www.sec.gov/Archives/edgar/data/1604477/000095017023028324/0000950170-23-028324-index.htm - Shareholder Votes SQZ Biotechnologies Co shareholders approved To elect Howard Bernstein, M.D., Ph.D., Paul Bolno, M.D., and Marc Schegerin, M.D. as Class III directors to serve until the 2026 annual meeting of stockholders at the 2023-06-14 meeting. - Proposal: director election - Outcome: passed - Meeting: 2023-06-14 source text: Item 1: To elect Howard Bernstein, M.D., Ph.D., Paul Bolno, M.D., and Marc Schegerin, M.D. as Class III directors to serve until the 2026 annual meeting of stockholders and until their respective successors shall have been duly elected and qualified. Class III Director Nominee For Withheld/Abstain Broker Non-Votes Howard Bernstein, M.D., Ph.D. 16,899,144 329,331 6,328,201 Paul Bolno, M.D. 15,368,658 1,859,817 6,328,201 Marc Schegerin, M.D. 16,908,459 320,016 6,328,201 evidence_url: https://www.sec.gov/Archives/edgar/data/1604477/000095017023028324/0000950170-23-028324-index.htm - Shareholder Votes SQZ Biotechnologies Co shareholders approved To approve amendments to the Company's restated certificate of incorporation, as amended, to effect a reverse stock split of the Company's common stock at a ratio ranging from any whole number between 1-for-10 and 1-for-20, as determined by the Board of Directors in its discretion at the 2023-06-14 meeting. - Proposal: reverse split - Outcome: passed - Meeting: 2023-06-14 source text: Item 2: To approve amendments to the Company's restated certificate of incorporation, as amended, to effect a reverse stock split of the Company's common stock at a ratio ranging from any whole number between 1-for-10 and 1-for-20, as determined by the Board of Directors in its discretion, subject to the Board of Directors' authority to abandon such amendments. For Against Withheld/Abstain Broker Non-Votes 23,057,854 476,649 22,173 0 evidence_url: https://www.sec.gov/Archives/edgar/data/1604477/000095017023028324/0000950170-23-028324-index.htm - Shareholder Votes SQZ Biotechnologies Co shareholders approved To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-14 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2023-06-14 source text: Item 3: To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. For Against Withheld/Abstain Broker Non-Votes 23,524,918 28,685 3,073 0 evidence_url: https://www.sec.gov/Archives/edgar/data/1604477/000095017023028324/0000950170-23-028324-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.